SCHEMBL7344179

SCHEMBL7344179

N#Cc1ccc2cc(C#CCCCc3ccccc3)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.46
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
FFAR1 O14842 2/20 0.42
FFAR4 Q5NUL3 1/20 0.41
ASIC3 Q9UHC3 1/20 0.41
CYP19A1 P11511 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
KLKB1 P03952 1/20 0.39
PRSS1 P07477 1/20 0.39
ABCG2 Q9UNQ0 2/20 0.39
NAMPT P43490 1/20 0.39
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7339939 0.91 FFAR1 (0.50) GRM5MAOBMAOAFFAR1FFAR4
SCHEMBL7345248 0.83 ASIC3 (0.46) MAOBMAOAFFAR1FFAR4ASIC3
SCHEMBL7338543 0.78 PLAU (0.49) MAOBMAOAFFAR1FFAR4ASIC3
SCHEMBL21623468 0.77 TSHR (0.50) GRM5MAOBMAOAFFAR1FFAR4
SCHEMBL29187194 0.77 GRM5 (0.54) GRM5MAOAFFAR1FFAR4
SCHEMBL2232651 0.77 CHRNA3 (0.42) CYP11B1CYP11B2F2PLGPLAU
SCHEMBL13087641 0.76 FFAR1 (0.51) GRM5MAOBMAOAFFAR1FFAR4
SCHEMBL7339947 0.75 ASIC3 (0.49) MAOBMAOAFFAR1FFAR4ASIC3
SCHEMBL7339709 0.73 ASIC3 (0.58) GRM5FFAR1ASIC3CYP19A1CYP11B1
SCHEMBL13087772 0.73 GRM5 (0.48) GRM5FFAR1FFAR4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 GRM5 4207/4885MAOB 666/4885MAOA 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.